Jeet Mukherjee Analyst PerformanceVice President & Biotechnology Analyst at BTIG ResearchJeet Mukherjee is a stock analyst at BTIG Research in the medical sector, covering 15 publicly traded companies. Over the past year, Jeet Mukherjee has issued 57 stock ratings, including strong buy, buy, and hold recommendations. While full access to Jeet Mukherjee's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jeet Mukherjee's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings57 Last 0 YearsBuy Recommendations98.21% 55 Buy RatingsCompanies Covered15 Unique Companies Ratings Distribution56RatingsDistribution of strong buy, buy, hold, and sell ratings by Jeet Mukherjee.RatingPercentageCount Strong Buy10.7%6 ratings Buy87.5%49 ratings Hold1.8%1 ratings Sell0.0%0 ratingsOut of 56 total stock ratings issued by Jeet Mukherjee at BTIG Research, the majority (87.5%) have been Buy recommendations, followed by 10.7% Strong Buy and 1.8% Hold.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ93.3% of companies on NASDAQ14 companiesNYSEAMERICAN6.7% of companies on NYSEAMERICAN1 companyJeet Mukherjee, an analyst at BTIG Research, currently covers 15 companies listed on NASDAQ and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical15 companies100.0%Jeet Mukherjee of BTIG Research specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE14 companies93.3%SURGICAL & MEDICAL INSTRUMENTS1 company6.7% About Jeet MukherjeeJeet Mukherjee, PhD, is a Vice President and Biotechnology Analyst at BTIG. Prior to joining BTIG, Mr. Mukherjee was a Senior Associate at Casdin Capital where he focused on public and private investments in the therapeutics space. Previously, he was a Senior Associate on the biotechnology equity research team at Jefferies. Mr. Mukherjee earned his PhD in pharmacology from Weill Cornell Medical College and his bachelor’s degree in biology from the University of Delaware.Follow on LinkedIn Jeet Mukherjee's Ratings History at BTIG Research Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsAARDAardvark Therapeutics5/15/2026Downgrade$4.97Hold$0.0000.00% ROIARVNArvinas5/13/2026Boost Price Target$9.57$18.00Buy$0.0000.00% ROIVSTMVerastem5/8/2026Lower Price Target$5.66$18.00Buy$0.0000.00% ROIVKTXViking Therapeutics5/1/2026Reiterated Rating$30.00$125.00Buy$0.0000.00% ROIVSTMVerastem4/20/2026Reiterated Rating$6.57$19.00Buy$0.0000.00% ROIAAPGAscentage Pharma Group International4/13/2026Reiterated Rating$25.33$48.00Buy$0.0000.00% ROIVSTMVerastem4/10/2026Reiterated Rating$5.35$19.00Buy$0.0000.00% ROIAAPGAscentage Pharma Group International3/26/2026Reiterated Rating$21.34$48.00Buy$0.0000.00% ROIAARDAardvark Therapeutics3/24/2026Reiterated Rating$4.07$9.00Buy$0.0000.00% ROIARVNArvinas3/19/2026Boost Price Target$10.89$16.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. CATXPerspective Therapeutics3/17/2026Reiterated Rating$5.22$14.00Buy$0.0000.00% ROIVSTMVerastem3/12/2026Initiated Coverage$6.19$19.00Buy$0.0000.00% ROIIPHAInnate Pharma3/12/2026Initiated Coverage$1.55$8.00Buy$0.0000.00% ROIIBRXImmunityBio3/12/2026Initiated Coverage$8.27$13.00Buy$0.0000.00% ROIAAPGAscentage Pharma Group International3/12/2026Initiated Coverage$24.22$48.00Buy$0.0000.00% ROIAVBPArriVent BioPharma3/12/2026Initiated Coverage$24.61$42.00Buy$0.0000.00% ROIAAPGAscentage Pharma Group International3/11/2026Upgrade$24.43Strong-Buy$0.0000.00% ROIAVBPArriVent BioPharma3/11/2026Upgrade$23.90Strong-Buy$0.0000.00% ROIIBRXImmunityBio3/11/2026Upgrade$8.39Strong-Buy$0.0000.00% ROIIPHAInnate Pharma3/11/2026Upgrade$1.50Strong-Buy$0.0000.00% ROIVSTMVerastem3/11/2026Upgrade$5.60Strong-Buy$0.0000.00% ROIAARDAardvark Therapeutics3/2/2026Lower Price Target$12.49$9.00Buy$0.0000.00% ROIKYMRKymera Therapeutics2/26/2026Lower Price Target$90.87$134.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics2/25/2026Boost Price Target$120.41$215.00Buy$0.0000.00% ROIMNPRMonopar Therapeutics2/23/2026Reiterated Rating$55.41$104.00Buy$0.0000.00% ROIAARDAardvark Therapeutics2/10/2026Reiterated Rating$12.98$26.00Buy$0.0000.00% ROIKYMRKymera Therapeutics2/3/2026Reiterated Rating$75.62$138.00Buy$0.0000.00% ROIMNPRMonopar Therapeutics2/2/2026Reiterated Rating$60.38$104.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics1/29/2026Reiterated Rating$78.71$192.00Buy$0.0000.00% ROINRIXNurix Therapeutics1/29/2026Reiterated Rating$17.87$30.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics1/16/2026Reiterated Rating$102.00$192.00Buy$0.0000.00% ROIBCAXBicara Therapeutics1/15/2026Reiterated Rating$17.07Buy$0.0000.00% ROIKYMRKymera Therapeutics1/15/2026Reiterated Rating$75.21$138.00Buy$0.0000.00% ROIMNPRMonopar Therapeutics1/14/2026Reiterated Rating$67.04$104.00Buy$0.0000.00% ROICATXPerspective Therapeutics1/13/2026Reiterated Rating$2.41$14.00Buy$0.0000.00% ROIBCAXBicara Therapeutics1/8/2026Initiated Coverage$17.17$28.00Buy$0.0000.00% ROIBCAXBicara Therapeutics1/8/2026Initiated Coverage$16.56$28.00Buy$0.0000.00% ROIFHTXFoghorn Therapeutics12/18/2025Initiated Coverage$4.64$11.00Buy$0.0000.00% ROIFHTXFoghorn Therapeutics12/18/2025Initiated Coverage$5.00$11.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics12/15/2025Boost Price Target$88.98$192.00Buy$0.0000.00% ROISpaceX is chump change compared to Elon’s $20T ‘iPhone’ (Ad)Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider sources say Elon Musk is developing a breakthrough technology he describes as '10x bigger than the largest product in history.' Nvidia's CEO has called it 'the next biggest opportunity after AI,' with potential lifetime sales reaching $20 trillion. A launch date of July 22nd is on the radar for early investors positioning ahead of the announcement.Get the full details on this opportunity before the launch date arrivesNRIXNurix Therapeutics12/9/2025Boost Price Target$21.47$30.00Buy$0.0000.00% ROIKYMRKymera Therapeutics12/8/2025Set Price Target$94.30$138.00$0.0000.00% ROIKYMRKymera Therapeutics12/8/2025Boost Price Target$94.23$138.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics12/5/2025Initiated Coverage$93.80$167.00Buy$0.0000.00% ROIPVLAPalvella Therapeutics12/5/2025Initiated Coverage$100.91$167.00Buy$0.0000.00% ROIAARDAardvark Therapeutics11/7/2025Initiated Coverage$9.87$26.00Buy$0.0000.00% ROINRIXNurix Therapeutics11/4/2025Reiterated Rating$12.62$27.00Buy$0.0000.00% ROIARVNArvinas10/30/2025Boost Price Target$9.59$14.00Buy$0.0000.00% ROINRIXNurix Therapeutics10/23/2025Lower Price Target$10.63$27.00Buy$0.0000.00% ROIKYMRKymera Therapeutics10/22/2025Boost Price Target$58.32$75.00Buy$0.0000.00% ROICATXPerspective Therapeutics10/10/2025Initiated Coverage$3.86$14.00Buy$0.0000.00% ROICATXPerspective Therapeutics10/10/2025Upgrade$4.83$14.00Strong-Buy$0.0000.00% ROIMNPRMonopar Therapeutics9/25/2025Boost Price Target$73.04$104.00Buy$0.0000.00% ROIARVNArvinas9/18/2025Lower Price Target$7.75$10.00Buy$0.0000.00% ROIMNPRMonopar Therapeutics9/15/2025Reiterated Rating$48.51$87.00Buy$0.0000.00% ROIMNPRMonopar Therapeutics9/9/2025Initiated Coverage$41.48$87.00Buy$0.0000.00% ROIKYMRKymera Therapeutics6/26/2025Reiterated Rating$46.47$59.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
